COFG Advisors LLC Takes Position in Celcuity, Inc. $CELC

COFG Advisors LLC purchased a new stake in Celcuity, Inc. (NASDAQ:CELC) during the fourth quarter, according to its most recent 13F filing with the SEC. The firm purchased 12,291 shares of the company’s stock, valued at approximately $1,226,000.

A number of other institutional investors have also modified their holdings of the company. Vanguard Group Inc. lifted its stake in Celcuity by 23.5% during the 3rd quarter. Vanguard Group Inc. now owns 2,059,047 shares of the company’s stock valued at $101,717,000 after acquiring an additional 391,262 shares during the period. New York State Common Retirement Fund increased its holdings in shares of Celcuity by 68.0% during the 3rd quarter. New York State Common Retirement Fund now owns 47,704 shares of the company’s stock valued at $2,357,000 after purchasing an additional 19,313 shares in the last quarter. Candriam S.C.A. increased its holdings in shares of Celcuity by 48.3% during the 3rd quarter. Candriam S.C.A. now owns 390,924 shares of the company’s stock valued at $19,312,000 after purchasing an additional 127,348 shares in the last quarter. Choreo LLC purchased a new position in shares of Celcuity during the 3rd quarter valued at approximately $248,000. Finally, TD Asset Management Inc purchased a new position in shares of Celcuity during the 3rd quarter valued at approximately $3,596,000. 63.33% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several equities analysts have recently weighed in on the stock. Craig Hallum reaffirmed a “buy” rating and set a $189.00 target price on shares of Celcuity in a report on Monday, May 4th. Macquarie Infrastructure set a $160.00 target price on shares of Celcuity in a report on Thursday. Wall Street Zen lowered shares of Celcuity from a “hold” rating to a “sell” rating in a report on Saturday, April 25th. Citizens Jmp lifted their target price on shares of Celcuity from $150.00 to $160.00 and gave the company a “market outperform” rating in a report on Monday, May 4th. Finally, Guggenheim lifted their target price on shares of Celcuity from $135.00 to $165.00 and gave the company a “buy” rating in a report on Monday, May 4th. Eleven investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, Celcuity currently has a consensus rating of “Moderate Buy” and a consensus target price of $150.27.

Insider Activity

In other news, Director Richard E. Buller sold 9,000 shares of the stock in a transaction dated Monday, May 4th. The shares were sold at an average price of $140.46, for a total transaction of $1,264,140.00. Following the sale, the director owned 6,760 shares of the company’s stock, valued at approximately $949,509.60. This represents a 57.11% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director David Dalvey sold 25,000 shares of the stock in a transaction dated Monday, May 4th. The stock was sold at an average price of $140.68, for a total transaction of $3,517,000.00. Following the sale, the director directly owned 65,000 shares in the company, valued at $9,144,200. This represents a 27.78% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 37,000 shares of company stock worth $5,111,950 in the last three months. Corporate insiders own 13.33% of the company’s stock.

Celcuity Trading Down 7.5%

Shares of CELC stock opened at $122.96 on Tuesday. The company’s 50-day moving average price is $123.29 and its 200-day moving average price is $111.48. The company has a current ratio of 12.31, a quick ratio of 12.31 and a debt-to-equity ratio of 6.04. The stock has a market cap of $6.00 billion, a price-to-earnings ratio of -31.53 and a beta of 0.09. Celcuity, Inc. has a twelve month low of $10.60 and a twelve month high of $151.02.

Celcuity (NASDAQ:CELC) last posted its earnings results on Thursday, May 14th. The company reported ($0.97) EPS for the quarter, beating analysts’ consensus estimates of ($1.07) by $0.10. As a group, equities analysts predict that Celcuity, Inc. will post -3.96 earnings per share for the current year.

Celcuity Company Profile

Celcuity, Inc is a clinical-stage biotechnology company specializing in precision oncology diagnostics. The company develops and commercializes predictive biomarker assays designed to identify which patients are most likely to benefit from targeted cancer therapies. By integrating functional profiling of tumor cells with molecular analyses, Celcuity seeks to optimize treatment selection and improve outcomes for patients with solid tumors.

Celcuity’s proprietary platform evaluates tumor cell sensitivity to various therapeutic agents using ex vivo assays that measure DNA damage response and other critical pathways.